Superior Efficacy of Denosumab over Zoledronic Acid in Increasing Femoral Neck Bone Mineral Density in Osteoporosis Patients with Type 2 Diabetes Mellitus

Key Points

• Denosumab demonstrates a greater increase in femoral neck bone mineral density compared to zoledronic acid, showcasing its efficacy.
• The study shows a 15% greater improvement in bone mineral density after treatment with denosumab over zoledronic acid.
• Analysis of treatment effects using bone mineral density measurements highlights the superiority of denosumab in osteoporosis management.
• The findings suggest a potential preference for denosumab in osteoporosis patients with type 2 diabetes, emphasizing better treatment outcomes.